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Biological therapy iscurrently being investigated in thetreatment ofa numberofmalignancies.
The hypothesis fortheuseofthis therapeutic modality involves anattempt tostimulatean already
existent but perhaps suboptimal immune response to foreign protein, including tumor. Immuno-
logic therapy appears towork bestagainst small-volume disease, as indicated from animal studies.
This condition is potentially achievable in advanced ovarian cancer, where surgery is capable of
producing multi-log reductions in tumor mass, and thus immunotherapy may be an option in this
disease. The attraction ofbiologic therapy in patients with ovarian cancer is the potential to treat
relatively localized but often chemotherapy-resistant disease. In cervical cancer, the rationale for
the use ofinterferon is somewhat different in that this disease may be a manifestation ofa virally
induced proliferative lesion. Thus, the antiviral properties ofinterferon are being investigated in
both limited and advanced cervical cancer. Both of these hypotheses have pre-clinical data to
support them. This paper presents the pre-clinical and clinical work currently available for
consideration offuture use.
OVARIAN CARCINOMA
Introduction
Despite objective response rates of 70-80 percent to combination chemotherapy,
advanced ovarian carcinoma has proven a frustrating disease to treat, because of the
rapid emergence of primary drug resistance and associated cross-resistance [1]. This
resistance remains a major clinical problem in spite of aggressive multimodality
therapy, regional dose intensification with intraperitoneal therapy, and high-dose
systemic therapy with autologous bone marrow rescue. Therefore, new approaches to
therapy are being sought, including an investigation ofthe activity ofbiologicals.
Since ovarian cancer remains confined to the peritoneal cavity for most of the
natural history of the disease, the concept of intraperitoneal therapy is attractive.
While intraperitoneal (IP) chemotherapy has been explored with some success, more
recently interest has turned to the study of biologic agents. One hypothesis is that
biological therapy stimulates an already existent but perhaps suboptimal immune
response to the presence of tumor by using significantly larger amounts of biological
agents than are produced naturally. Two approaches being investigated in ovarian
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carcinoma are the use of cytokines alone and cytokines in conjunction with their
effector cells, which are presumed to mediate immune destruction oftumors.
The human stem cell assay provided initial clues that biologicals may have activity
against ovarian carcinoma [2,3], leading to investigation of biological therapy,
particularly interferons (IFNs), which stimulate natural killer (NK) cells in vitro and
in vivo. Investigators havereported diminished NK cell activity in the peritoneal cavity
of women with ovarian carcinoma previously treated with chemotherapy [4]. There-
fore, the potential for immune stimulation byadministration ofinterferon is appealing.
Initial studies with IP administration of Corynebacterium parvum also gave clues to
the potential for an immune approach, produced intense peritonitis, possibly leading to
localized immune stimulation, and resulting in true measurable responses [5].
Interferons (IFNs)
These polypeptide products ofactivated lymphoid cells are the prototype ofbiologic
response modifiers and induce a wide range of physiologic changes [6]. Studies of
interferons initially utilized a partially purified substance that contained a mixture of
cytokines, but the substances now used are highly purified products of recombinant
DNA technology.
There are three distinct antigenic types of interferon, designated a, ,B, and 'y.
Interferon-a, usually thought ofas leukocyte IFN, is thesubstance most widely used in
clinical trials. IFN-f3, derived from fibroblasts, has properties similar to IFN-a,
including binding to the same receptor. IFN--y, often called immune interferon, is
derived from T lymphocytes and is quite different from the other two interferons. For
example, while both IFN-a and IFN-,B are both strong inducers ofNK activity, IFN-y
appears to stimulate monocytes and macrophages selectively.
Natural Killer (NK) Cells
NK cells are a subpopulation of normal lymphoid cells with spontaneous cytotoxic
reactivity against a variety of tumor cells; NK cells can be rapidly augmented by in
vivo or in vitro administration ofinterferon [7]. There is increasing evidence that NK
cells may mediate the natural immune response in vivo against tumor cells and may
play an important role in immune surveillance [7,8]. NK cells are included in a
morphologically identifiable subpopulation of cells, large granular lymphocytes
(LGLs), which comprise approximately 5 percent ofthe blood peripheral mononuclear
leukocytes. Therefore, LGLs would be a logical choice as effectorcells for adoptive cell
transfer. In addition, when radiolabeled LGLs and thymus-derived lymphocyte
(T-cell) populations were administered intraperitoneally, less than 20 percent of the
cells were found tomigrate from theperitoneal cavitywithin 24 hours after inoculation
[9].
Clinical Trials with Interferons in Ovarian Cancer
Initial clinical trials employed systemic administration ofinterferon. Einhorn et al.
demonstrated evidence of clinical activity when daily intramuscular purified alpha
interferon, 3 million units (MU)/day, was given to fivepatients with advanced ovarian
carcinoma [10]. Ascitic fluid production ceased in two patients with ascites, and both
remained stable for more than one year. A third patient had a partial response (50
percent or greater reduction in tumor) lasting two months. Also of importance, the
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administration ofinterferon was followed byan increase in natural killercell activity in
peripheral blood lymphocytes, suggesting enhancement of immune activity. Subse-
quently, others have investigated IP interferon based on the premise discussed earlier,
that relatively refractory residual disease remains in the peritoneal cavity.
IPAlpha Interferon (IFN-a)
Berek et al. have reported a nicely designed study in which 14 patients with
persistent ovarian cancer limited to the peritoneal cavity and verified at second-look
surgery were treated with IP recombinant alpha interferon [ 1]. Both the clinical and
immunological parameterswerefollowed during thecourseoftreatment. Priortherapy
included one to three surgeries, as well as a median of nine cycles of combination
chemotherapy. Two patients had previously received pelvic irradiation.
Patients received IP interferon administered in 250 ml normal saline following
instillation of 1,750 ml ofdialysis solution via a Tenckhoffcatheter. Ten patients were
treated on a weekly dose-escalation schedule of5 x 106 units, 10 x 106units, 20 x 106
units, then 50 x 106 units weekly thereafter. A second dose schedule attempted 50 x
106 units three times a week, but toxicity precluded more than weekly administration
ofthis dose.
Eleven patients were evaluated surgically for clinical response, and three were
evaluated clinically only. Four patients (36 percent) demonstrated pathologically
documented complete response, and one patient a partial response. The remaining six
patients, evaluated surgically, showed progressive disease.
All of the five responders had minimal residual tumor, less than 5 mm prior to
beginning IPinterferon, whereas fourpatients with diseasegreater than 5 mm failed to
respond. Thedurationofresponsewas reported as 5-14+ months. Thus, tumor burden
prior to initiation of therapy may well be a factor in response. Of the three patients
evaluated clinically only, one had a complete clinical response with total resolution of
ascites, while the others were stable or progressed.
Toxicity with this approach was consistent with that seen after systemic administra-
tion ofa-interferon, including fatigue, chills, anorexia, and headaches. One-quarter of
patients experienced local complaints of nausea/vomiting, diarrhea, and abdominal
pain, probably related to receiving IP therapy. Hematologic toxicity also occurred in
this group ofheavily pre-treated patients but was primarily a mild to moderate anemia
and a mild decrease in white blood cells (2,000/,al).
Concomitant immunologic studies were performed, including lymphocyte count in
both the peripheral blood and peritoneal washings, and NK activity was assessed in
both blood and peritoneal fluid. These studies showed a decrease in peripheral
lymphocytes during each cycle, with a subsequent return to baseline. In the peritoneal
fluid a consistent increase, nearly a doubling, of mononuclear cells was seen after
treatment. NK activity was significantly augmented in the peritoneal fluid, although
not in the peripheral blood. Boosting of NK activity did not uniformly correlate with
response, however.
Thus, alpha interferon appears to have activity in maximally resected ovarian
carcinoma. There is also evidence that interferons may act synergistically with
cytotoxic chemotherapeutic agents in vitro and this finding has potential for clinical
investigation.
369DUTCHER ET AL.
Beta Interferon (IFN-/3)
At least one study ofIFN-f administered by the IP route to ovarian cancer patients
has been reported [14]. Eight patients with chemotherapy-resistant, advanced intra-
peritoneal disease (seven had ascites and five had measurable masses) received 3 x 106
units ofIFN-f3 twice weekly.
Seven of eight had ascites prior to starting therapy and four of seven had total
cessation of ascites with IP IFN-f3 therapy. The ascites-free intervals were six weeks,
eight weeks, ten months, and 15 months. The last patient maintained stable disease for
15 months and survived 24+ months from time on study. Toxicities were similar to
those seen with a-interferon, except that there was no hematologic toxicity on this
schedule and dose. An increase in NK activity ofthe intraperitoneal lymphocytes was
observed in two patients, with no effect on peripheral blood lymphocytes.
Apart from the palliative effect on ascites, there were only two patients with
prolonged stable disease. Nevertheless, in this group of patients with large-bulk
disease, this result would appear to demonstrate activity. Further studies in minimal-
bulk disease are warranted.
Gamma Interferon (IFN-Ty)
There are in vitro data demonstrating anti-tumor efficacy ofIFN-'Y against ovarian
cancer tumor cells. Cytotoxicity studies of treatment with both IFN-'y alone and with
the addition ofIFN-y-treated macrophages showed anti-tumor activity [15].
Clinical studies are quite preliminary, demonstrating that this drug can be adminis-
tered safely by this route (IP). Markman et al. have reported a phase I, dose-escalation
study of 27 patients with refractory ovarian cancer treated with weekly IP IFN--Y
[16,17]. The doses ranged from 0.1 to 8.0 x 106 u/M2. Intraperitoneal peak levels of
IFN--y were 150-200 times higher than levels in the systemic circulation. All patients
in this study demonstrated progressive disease, including five patients evaluated
surgically. Ofthe 27 patients, six were considered to have minimal disease at the time
of IP treatment. Toxicity in this dose range seemed less than that described with IP
IFN-a.
Thus, IFN--y in one phase I study did not demonstrate the level ofactivity observed
in single-institution studies with IP IFN-a or IFN-3 in IPovarian cancer; however, the
biologically active dose may not have been established. In addition, IFN-a may
potentiate the effects of IFN--y so that combinations of biologics or combinations of
biologics with chemotherapy remain possibilities open for further investigation.
In summary, interferons administered intraperitoneally in patients with minimal
residual IP ovarian cancer have demonstrated benefit. Further optimization and
exploration ofsuch therapy is warranted.
Interleukin-2 (IL-2)
The interleukins are part of a family of proteins known as cytokines, produced by
lymphocytes and macrophages, which stimulate interactions between thevarious types
of mononuclear white blood cells and potentiate a variety of intercellular activities.
Interleukin-2, originally described as T-cellgrowth factor [18], stimulates the immune
responsiveness of a variety of populations of lymphocytes, including natural killer
(NK) cells [19], T-cytotoxic cells [20], and the lymphocytes that mediate lymphokine
activated killer (LAK) activity [21]. Interleukin-2 is being actively investigated as a
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stimulator and potentiator of these killer lymphocytes that have cytotoxic activity
against tumor cells and is being utilized as the stimulating substance in adoptive
immunotherapy. In adoptive immunotherapy, the approach is the initial in vivo
stimulation of lymphocyte activation with IL-2, followed by in vitro expansion and
further activation of these cells, followed by re-infusion of the activated lymphocytes
with additional IL-2 [22,23]. The expectation is that such activated killer cells will be
selectively cytotoxic to tumor cells.
LAK Cells or LAKActivity
Lymphokine activated killer cell activity is a functional definition of the activity of
what may be a heterogeneous population of lymphocytes capable of antitumor
cytotoxicity [21]. By definition, LAK cells are capable of lysing fresh tumor targets,
including targets derived from ovarian ascites, and they can lyse target cell lines which
are normally resistant to NK cells. Thus, LAK cells have properties different from
T-cytotoxic cells or NK cells, but all of these killer cells respond to IL-2 and are
probably closely related [24]. LAK cells are stimulated by IL-2. NK cells are also
stimulated by IL-2 and by interferon.
Modelfor theStudy ofNew Therapy in Ovarian Carcinoma
Animal models relevant to the study of ovarian carcinoma have been recently
improved with the development of the National Institutes of Health NIH:OVCAR-3
cell line [25,26]. This line was derived from a patient with malignant ascites, who was
clinically resistant to chemotherapy. The cell line has the capacity to grow in tissue
culture and as a xenograft in nude mice. This tumor expresses estrogen and androgen
receptors and CA-125. It also has karyotypic abnormalities characteristic of ovarian
carcinoma (changes in ploidy) andthosepossibly related todrug-resistant cells (double
minute chromosomes and homogeneous staining regions).
A specific subpopulation ofthis human ovarian tumor cell line iscapableofinducing
ascites and intraperitoneal malignancy in nude mice [26]. This subpopulation main-
tains all oftheidentifying characteristics oftheoriginal tumor and is being used widely
to study the issues of drug resistance and the impact of hormonal therapy on ovarian
carcinoma.
This model provides characteristics of ovarian carcinoma which have not been
demonstrated by othercell systems: (a) histopathology and embryology consistent with
human ovarian cancer, (b) a reproducible pattern ofmetastases which parallels human
disease, (c) drug sensitivity profiles similar to that of human ovarian cancer, (d)
immunological and biological properties consistent with human ovarian cancer, and (e)
suitable markers to follow response to treatment.
The pattern of metastases and the human derivation of this subpopulation model
make this cell line useful for evaluation of experimental therapy, such as activated
natural killer cells or T lymphocytes, mullerian regression substance, bacterial toxins,
and monoclonal antibodies conjugated to toxic substances.
AnimalStudies ofAdoptive Immunotherapy in Ovarian Cancer
Ortaldo et al., using the modification of NIH:OVCAR-3 described earlier as a
xenograft in nude mice, studied the efficacy of adoptive immunotherapy in ovarian
carcinoma [23]. This group studied activated lymphocytes stimulated by interleukin-2
and monocytes stimulated bygamma interferon. Data from this group have shown that
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80 percent of radiolabeled large granular lymphocytes and T cells remain in the
peritoneal cavity within 24 hours after inoculation [9].
Animals that were given injections of five doses of untreated LGL with or without
IL-2 simultaneously demonstrated no significant increase in mean or median survival
time. Animals that were given multiple injections of both IL-2 and IL-2 pre-treated
LGL, however, demonstrated a significant increase in mean survival time.
Because these results were achieved with, presumably, NK cells, although the
requirement for pre-activation with IL-2 for cytotoxicity defines LAK activity ofthese
lymphocytes, other effector cells were specifically evaluated. In a manner similar to
that of LGL, when T cells were stimulated with IL-2, cytotoxic activity was induced,
and there was a significant extension in mean and median survival of the subset of
animals in which the lymphocytes were pre-exposed to IL-2 and had continued
exposure to IL-2 following re-infusion into the peritoneal cavity. Injection of IL-2
alone induced no significant extension ofsurvival time.
Similar treatment with monocytes activated with gamma interferon demonstrated
only a small but insignificant improvement in the mean and median survival time,
suggesting that this cytokine effector system is not as important in the clinical
improvement.
Thus, activation with IL-2 ofa mixed population ofeffector cells, including NK and
T-cytotoxic cells, produces functionally defined LAK activity, which is cytotoxic to
tumor in this murine model ofovarian cancer. Significant survival benefit was noted in
these animals.
Human Clinical Results ofAdoptive Immunotherapy in Ovarian Carcinoma
To explore the potential for site-directed adoptive immunotherapy, Allavena et al.
have demonstrated that the peripheral blood lymphocytes (PBLs) and the tumor-
associated lymphocytes (TALs) of patients with advanced ovarian cancer and ascites
are activated after culture with IL-2 [27,28]. Cytotoxicity was demonstrated against
autologous ovarian tumor cells as well as NK-sensitive (K562) and NK-resistant
(Daudi) cell targets. Thus, LAKactivity could be induced after culture with IL-2. The
TALs in particular had poor cytotoxic activity prior to culture with IL-2 and
demonstrated markedly improved cytotoxicity after culture.
The intraperitoneal route of therapy is attractive in ovarian carcinoma and the
surgical oncology group at the National Cancer Institute (NCI) has utilized this route
in the administration of IL-2 in a number of different diseases [29]. One patient with
ovarian carcinoma metastatic to liver, without ascites, was treated among a group of
seven patients (three colon, three melanoma). She received 1 to 2, 10,000 u/kg every
eight hours for five days, resulting in significant toxicity requiring ventilatory support,
but without response to anti-tumor therapy. In general, however, among the other
patients treated, toxicity from IP administration of IL-2 was no greater than with
systemic administration. Interestingly, one patient with melanoma metastatic to lungs
who received IP IL-2 had a dramatic response of lung metastases, verifying that this
route ofadministration is feasible in humans.
West et al. have recently published their experience with continuous infusion IL-2
and LAK cell adoptive immunotherapy [30]. One patient with ovarian carcinoma was
among their 48 patients treated with systemic IL-2. This patient had a bulky
abdominal wall mass and responded to IL-2/LAK with a 50 percent reduction in
tumor, which lasted two months.
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A phase I pilot study of IP recombinant IL-2 was reported in abstract form with IP
IL-2 administered three times per week, in escalating doses [31]. There was consider-
able patient-to-patient variability in the clearance of IL-2 from the peritoneal cavity.
Augmentation of peripheral blood NK activity was seen in three of three patients, and
augmentation of LAK activity in peritoneal lymphocytes was seen in two of three
patients. Peripheral LAK activity was generated in three of three patients. Although
measurable response was not a goal of this feasibility study, one of two patients
demonstrated a marked decrease in CA-125 levels with this therapy.
Thus, there are substantial preliminary data to suggest that biological therapy has a
role in the treatment of ovarian carcinoma, particularly in patients with minimal
residual disease. The caveats are that these are small numbers ofpatients, often highly
selected, and these data are quite preliminary. In addition, there has been no
prospective comparison to the natural history of patients with minimal disease to
demonstrate improved survival. Further investigation of adoptive immunotherapy is
currently under way at a number ofcenters, including the National Cancer Institute-
Biologic Response Modifier Program (NCI-BRMP) at Frederick and BRMP-
sponsored phase I-II clinical trials at other institutions, and we look forward to reports
of their results.
A POTENTIAL ROLE FOR RECOMBINANT ALPHA INTERFERON
AGAINST HUMAN CERVICAL CANCER
Despite large-scale programs for early detection and readily available treatments for
local disease, approximately 7,000 women die ofcarcinoma ofthe cervix yearly [31].
Factors in local failure include the uncertainties of lymphatic drainage; unfavorable
anatomic factors, such as a narrow (senile) vagina; unfavorable biologic factors, such
as bulky disease; and faulty management of the primary lesion or locoregional lymph
nodes [32]. Once the primary tumor has advanced beyond the true pelvis, theprognosis
for the patient is poor; currently available cytotoxic agents, whether given individually
[33,34] or in combination [35], rarely result in prolongation of survival beyond two
years. Thus, alternative therapeutic modalities are worth investigating in patients with
disseminated disease.
Epidemiologic observations clearly indicate that cervical carcinoma has many ofthe
attributes of a communicable disease [36]. Viruses are the leading contenders for a
major role in the induction ofcervical neoplasia, and, ofthese, the human papillomavi-
ruses (HPV) are the most likely carcinogens [37]. HPV is a double-stranded
deoxyribonucleic acid (DNA) virus which produces local infections of the epithelial
cells of the skin and mucus membranes [38]. It has recently been appreciated that
many of the dysplastic lesions of the cervix in fact represent infections with human
papillomaviruses [39-41]. Morphologic evidence for the involvement of HPV in
pre-cancerous lesions of the cervix includes the presence of koilocytotic and warty
atypia in cervical biopsies and cytologic smears with dysplasia [40], thedemonstration
of viral antigens in these tissues by immunocytochemical techniques [42], and the
identification of viral particles by electron microscopy [43]. In fact, HPV DNA
sequences have been identified in the majority of both pre-malignant and malignant
cervical tissues [44-47]. In addition, two animal papillomaviruses, Shope papillomavi-
rus and Bovine papillomavirus, are known to induce, in their natural host, papillomas
which may eventually become carcinomas, particularly in association with mutagenic
agents (reviewed in [48]). Molecular hybridization studies have amply documented
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the presence of HPV DNA within pre-cancerous lesions, pre-invasive lesions, and
frank carcinomas ofthe cervix [49-51].
Frankly invasive carcinoma ofthe cervix isvirtually ifnot always preceded by either
dysplasia or a benign, but pre-malignant neoplastic change; hence the diagnosis and
management ofpre-clinical carcinoma of the cervix has attracted much interest [52].
The presence of classic venereal warts (condyloma acuminata) in the cervix has been
well known for years [41,53]. The link between these benign lesions and both cervical
dysplasia and malignant transformation was not well characterized until 1976, when
two previously unrecognized forms of cervical condylomas were discovered [54,55].
These flat and inverted (endophytic) lesions closely mimicked cervical dysplasia,
carcinoma in situ and invasive squamous cell carcinoma [40,56].
Subsequently, abundant evidence has developed implicating condylomata acumi-
nata as a pre-malignant condition [40,41,56-58]. There is also a well-documented
association between this pre-malignant lesion and HPV. Gissmann examined 63
typical lesions, employing a DNA probe for HPV6 and 11, and found a total of 86
percent were positive for the viral genome [44,45]. Schinella et al. [59] found HPV6a
DNA fragments and HPV antigen in condylomata which underwent malignant
transformation. Electron micrographic examination of condyloma cells has revealed
large numbers of HPV particles [60].
There are, also, now well-established links between cervical HPV infections and
other pre-malignant or dysplastic conditions, including cervical intraepithelial neopla-
sia (CIN) [61-64], vaginal in situ carcinoma [65,66], and vulvar intraepithelial
neoplasia [67,68]. These data, along with epidemiologic evidence indicating that both
HPV infections of the genital tract and cervical neoplasia have similar risk factors,
including peak incidence in young, sexually promiscuous women with poor sexual
hygiene, now suggest that cervical cancer might reasonably be considered a sexually
transmitted disease [69,70].
Human papillomavirus-associated lesions appear to be exquisitely sensitive to
treatment with the antiviral, antineoplastic agent interferon. Olsen et al. have reported
that, among 34 patients with refractory condyloma acuminata treated in a random-
ized, double-blind trial, 17 (50 percent) had a response to human lymphoblastoid
interferon alpha (3 MU/M2 by intramuscular injection daily for two weeks, then three
times weekly for four weeks) [71]. In a study by Friedman-Kien et al., patients with
condylomata treated with intralesional "ultra-pure" IFN-alpha achieved complete
clearing of their lesions, and a sixth achieved a partial response [72]. In a larger
multicenter trial of intralesional therapy, 100,000 international units (IU) was
significantly better than placebo in reducing the size of the condylomata, with 53
percent ofIFN-treated patients achieving complete clearing oflesions [73].
Furthermore, among 13 patients with CIN and vulvar intraepithelial neoplasia
associated with HPV infection who were treated with intralesional human fibroblast
interferon, seven complete and two partial responses were observed by DePalo et al.
[74]. Likewise, intralesional interferon alpha or beta produced complete remission in
eight of 12 patients with CIN, while interferon gel produced complete remission in two
ofeight with CIN [75].
Thus, in light ofthe fact that cervical carcinoma is closely associated with HPV and
that pre-malignant lesions ofthe female genital tract appear to be exquisitely sensitive
to interferon treatment, it is rational to consider interferon therapy in the treatment of
disseminated cervical carcinoma.
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In one early study, patients with early-stage cervical carcinoma were treated with
crude human leukocyte interferon at a dose ofonly 10,000-50,000 units daily [76]. In
addition, in 6/15 patients, interferon was applied topically only. The typical tumor
regressed to one-third of its size, with histologic changes consistent with tumor
regression. While rigid criteria for tumor response were not applied, the investigators
describe an "excellent" and "verygood" response noted in 11 /15 patients. The Eastern
Cooperative Oncology Group (ECOG) is currently undertaking a phase II trial of
recombinant alpha-2b-interferon in patients with disseminated cervical carcinoma.
With thecharacterization ofover 30 typesofHPV, sensitive probes employing DNA
hybridization techniques are now available to detect the virus and its transcripts in
tumor specimens [77]. HPV genome has been isolated from cervicovaginal lavage
specimens from patients with dysplastic and neoplastic lesions and detected by
Southern blot analysis [78]. Thus, accurate correlations can now be made between the
presence, type, and expression ofviral genetic material in human tumors and response
ofthose tumors to antiviral agents. The ECOG study will correlate response to therapy
using interferon with presence of virus and viral subtypes in both primary and, when
feasible, metastatic disease. The results ofthis study will, it is hoped, help to elucidate
the mechanism ofantitumor activity ofalpha interferon in this disease.
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